Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis
Authors:
- Iain C MacdougallIMIain C Macdougall
- Robert ProvenzanoRPRobert Provenzano
- Amit SharmaASAmit Sharma
- Bruce S SpinowitzBSBruce S Spinowitz
- Rebecca J SchmidtRSRebecca J Schmidt
- Pablo E PergolaPPPablo E Pergola
- Raja I ZabanehRZRaja I Zabaneh
- Sandra Tong-StarksenSTSandra Tong-Starksen
- Martha R MayoMMMartha R Mayo
- Hong TangHTHong Tang
- Krishna R PoluKPKrishna R Polu
- Anne-Marie DuliegeADAnne-Marie Duliege
- 24 January 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (4) , 320-332
Abstract
Peginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have therapeutic potential for anemia in patients with advanced chronic kidney disease. We evaluated the safety and efficacy of peginesatide, as compared with another ESA, darbepoetin, in 983 such patients who were not undergoing dialysis. In two randomized, controlled, open-label studies (PEARL 1 and 2), patients received peginesatide once a month, at a starting dose of 0.025 mg or 0.04 mg per kilogram of body weight, or darbepoetin once every 2 weeks, at a starting dose of 0.75 μg per kilogram. Doses of both drugs were adjusted to achieve and maintain hemoglobin levels between 11.0 and 12.0 g per deciliter for 52 weeks or more. The primary efficacy end point was the mean change from the baseline hemoglobin level to the mean level during the evaluation period; noninferiority was established if the lower limit of the two-sided 97.5% confidence interval was −1.0 g per deciliter or higher. Cardiovascular safety was evaluated on the basis of an adjudicated composite end point. In both studies and at both starting doses, peginesatide was noninferior to darbepoetin in increasing and maintaining hemoglobin levels. The mean differences in the hemoglobin level with peginesatide as compared with darbepoetin in PEARL 1 were 0.03 g per deciliter (97.5% confidence interval [CI], −0.19 to 0.26) for the lower starting dose of peginesatide and 0.26 g per deciliter (97.5% CI, 0.04 to 0.48) for the higher starting dose, and in PEARL 2 they were 0.14 g per deciliter (97.5% CI, −0.09 to 0.36) and 0.31 g per deciliter (97.5% CI, 0.08 to 0.54), respectively. The hazard ratio for the cardiovascular safety end point was 1.32 (95% CI, 0.97 to 1.81) for peginesatide relative to darbepoetin, with higher incidences of death, unstable angina, and arrhythmia with peginesatide. The efficacy of peginesatide (administered monthly) was similar to that of darbepoetin (administered every 2 weeks) in increasing and maintaining hemoglobin levels. However, cardiovascular events and mortality were increased with peginesatide in patients with chronic kidney disease who were not undergoing dialysis. (Funded by Affymax and Takeda Pharmaceutical; ClinicalTrials.gov numbers, NCT00598273 [PEARL 1], NCT00598442 [PEARL 2], NCT00597753 [EMERALD 1], and NCT00597584 [EMERALD 2].)Keywords
This publication has 26 references indexed in Scilit:
- Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in ratsXenobiotica, 2011
- Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impactEuropean Journal of Clinical Pharmacology, 2010
- Novel Erythropoiesis-Stimulating AgentsClinical Journal of the American Society of Nephrology, 2008
- Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemiaExperimental Hematology, 2006
- Development and characterization of novel erythropoiesis stimulating protein (NESP)Nephrology Dialysis Transplantation, 2001
- Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 ÅScience, 1996
- Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietinThe Lancet, 1990
- Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal DiseaseAnnals of Internal Medicine, 1989
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986